9:00am - 5:00pm

Office Hours Mon. - Fri.

800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search

Study of PXD101 Alone and in Combination With 5-Fluorouracil (5-FU) in Patients With Advanced Solid Tumors

Estimated reading time: < 1 min

Condition

Tumor

Estimated Enrollment: 35

Age Group: 18 Years and older   (Adult, Senior)

Gender: All

Study Type: Interventional

Study Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment

Study ID Numbers: PXD101-CLN-4

Study First Received: December 18, 2006

Last Updated: July 7, 2015

Estimated Primary Completion Date: March 2008

Primary Outcome Measures:

to determine the maximum tolerated dose of PXD101 administered in combination with 5-FU|to determine whether PXD101 alone can down-regulate thymidylate synthase in patient tumors

Sponsors and Collaborators:

Onxeo

Result Received: No Study Results Posted

Website Link: https://ClinicalTrials.gov/show/NCT00413322

Was this article helpful?
Views: 7